Nutriband Inc. has announced a new partnership with Kindeva to develop Aversa™ Fentanyl, an innovative fentanyl patch that incorporates Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved patch. This collaboration marks a significant step towards creating a commercially viable product aimed at reducing the risk of abuse, misuse, and accidental exposure to fentanyl. With the commercial manufacturing process scale-up completed, the partnership aims to manufacture clinical supplies and file an Investigational New Drug $(IND.AU)$ application with the FDA. Aversa Fentanyl could become the first abuse-deterrent pain patch available on the market, enhancing the safety of transdermal drugs while ensuring accessibility for patients in need.